News 2022-03-02
Porton Plans to Invest 420 million to Expand CDMO Production Capacity of Small Molecule API
March 1st, 2022, Chongqing · China – Porton Pharma Solutions Ltd. announced an investment of 420 million to expand CDMO Production Capacity of Small Molecule API in Porton Pharma (Jiangxi) Co., Ltd. which is mainly engaged in customized production of APIs, intermediates and starting materials.
This expansion project will add 2 production workshops, utilities workshop, comprehensive warehouses and other facilities, which total construction area is 31,270㎡. With an estimated new production capacity of 300 m3, it is planned to be completed and put into operation by the end of 2023. In the future, Porton will undertake more high value-added intermediates and API production projects, which will help further consolidate the company's comprehensive capabilities as an End-to-End CDMO service platform.
Others
More
News 2026-09-17
Porton Congratulates Partner Acepodia on FDA and NMPA IND Approvals for ACE723, a Dual-Payload ADC
This project demonstrates Porton's process-development and scale-up capabilities for complex conjugates and adds to its experience supporting innovative biopharma companies worldwide.
News 2026-09-15
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
This successful recertification highlights the standardized operation of the site's management systems, the rigor of its on-site management, and the robustness of its risk control mechanisms, further validating the continued effectiveness of the dual systems.
